8 research outputs found
Characteristics of patients included in the nested case-control study.
<p>Characteristics of patients included in the nested case-control study.</p
Flow-chart of the study population of patients with hepatocellular carcinoma.
<p>Flow-chart of the study population of patients with hepatocellular carcinoma.</p
Kaplan Meier curve for cumulative incidence of thrombosis after liver transplantation.
<p>Kaplan Meier curve for cumulative incidence of thrombosis after liver transplantation.</p
Incidence rates of mortality and need of re-transplantation in patients with or without thrombosis.
<p>Incidence rates of mortality and need of re-transplantation in patients with or without thrombosis.</p
Characteristics of patients who underwent liver transplantation.
<p>Characteristics of patients who underwent liver transplantation.</p
Additional file 1: of Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis
Table S1. Characteristics of unmatched and matched treatment groups; The table shows the characteristics of patients who underwent TARE or sorafenib in unmatched and matched cohorts. (DOCX 14 kb
Additional file 3: of Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis
Appendix. CHEERS Checklist; The ISPOR CHEERS (Consolidated Health Economic Evaluation Reporting Standards) checklist shows recommended items to be included in reports of economic evaluations of health interventions. (PDF 108 kb
Additional file 4: of Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis
Table S2. Mean annual costs per patient for intermediate and advanced stages HCC related to TARE and sorafenib treatments; The table reports, for TARE and sorafenib, mean annual costs per patient for the following cost categories: first-line treatment, management of adverse events, visits/exams, subsequent treatments. (DOCX 18 kb